Iris Nederlof
Overview
Explore the profile of Iris Nederlof including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greenwald N, Nederlof I, Sowers C, Ding D, Park S, Kong A, et al.
bioRxiv
. 2025 Feb;
PMID: 39975273
Immune checkpoint inhibition (ICI) has fundamentally changed cancer treatment. However, only a minority of patients with metastatic triple negative breast cancer (TNBC) benefit from ICI, and the determinants of response...
2.
Bakker N, Garner H, van Dyk E, Champanhet E, Klaver C, Duijst M, et al.
NPJ Breast Cancer
. 2025 Jan;
11(1):5.
PMID: 39843922
Cancer disrupts intratumoral innate-adaptive immune crosstalk, but how the systemic immune landscape evolves during breast cancer progression remains unclear. We profiled circulating immune cells in stage I-III and stage IV...
3.
Nederlof I, Isaeva O, de Graaf M, Gielen R, Bakker N, Rolfes A, et al.
Nat Med
. 2024 Sep;
30(11):3223-3235.
PMID: 39284953
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could...
4.
Rumberger J, Greenwald N, Ranek J, Boonrat P, Walker C, Franzen J, et al.
bioRxiv
. 2024 Jun;
PMID: 38895405
Multiplexed imaging offers a powerful approach to characterize the spatial topography of tissues in both health and disease. To analyze such data, the specific combination of markers that are present...
5.
Nederlof I, Voorwerk L, Kok M
Clin Cancer Res
. 2023 Jan;
29(13):2362-2370.
PMID: 36622327
A substantial fraction of early-stage triple-negative breast cancer (eTNBC) is characterized by high levels of stromal tumor-infiltrating lymphocytes (sTIL) and has a good prognosis even without systemic treatment, highlighting the...
6.
Schirris Y, Gavves E, Nederlof I, Horlings H, Teuwen J
Med Image Anal
. 2022 May;
79:102464.
PMID: 35596966
We propose a Deep learning-based weak label learning method for analyzing whole slide images (WSIs) of Hematoxylin and Eosin (H&E) stained tumor tissue not requiring pixel-level or tile-level annotations using...
7.
Kester L, Seinstra D, van Rossum A, Vennin C, Hoogstraat M, van der Velden D, et al.
Clin Cancer Res
. 2021 Dec;
28(5):960-971.
PMID: 34965952
Purpose: Extensive work in preclinical models has shown that microenvironmental cells influence many aspects of cancer cell behavior, including metastatic potential and their sensitivity to therapeutics. In the human setting,...
8.
Van Bockstal M, Cooks M, Nederlof I, Brinkhuis M, Dutman A, Koopmans M, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638394
Patients with advanced triple-negative breast cancer (TNBC) benefit from treatment with atezolizumab, provided that the tumor contains ≥1% of PD-L1/SP142-positive immune cells. Numbers of tumor-infiltrating lymphocytes (TILs) vary strongly according...
9.
Hammerl D, Martens J, Timmermans M, Smid M, Trapman-Jansen A, Foekens R, et al.
Nat Commun
. 2021 Sep;
12(1):5668.
PMID: 34580291
Only a subgroup of triple-negative breast cancer (TNBC) responds to immune checkpoint inhibitors (ICI). To better understand lack of response to ICI, we analyze 681 TNBCs for spatial immune cell...
10.
Nederlof I, Horlings H, Curtis C, Kok M
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33467084
Providing effective personalized immunotherapy for triple negative breast cancer (TNBC) patients requires a detailed understanding of the composition of the tumor microenvironment. Both the tumor cell and non-tumor components of...